Skye Bioscience, Inc.

Listed Company

SKYECIK 0001516551NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsNevadaFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-55.92M

Total Assets

$28.31M

Equity

$20.02M

Shares Out

33.38M

Op. Cash Flow

$-43.06M

Business

Skye Bioscience, Inc. is a clinical‑stage biotechnology company that develops next‑generation molecules that modulate G‑protein‑coupled receptors (GPCRs) to treat obesity, overweight and related metabolic conditions. Its principal product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting the CB1 receptor, administered subcutaneously and evaluated as monotherapy and in combination with GLP‑1 receptor agonists. The company’s activities comprise clinical development, nonclinical studies, CMC and intellectual property management centered on a GPCR therapeutic platform. It conducts clinical trials primarily in the United States and relies on third‑party contract manufacturing and global regulatory pathways for development and distribution.

Summary from filing dated 2025-03-20

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development	42	19	6	6	—
General and administrative	16	18	8	6	5
Change in estimate for legal contingencies	0	−4	—	—	—
Income from insurance recovery	0	−2	0	—	—
Total operating expenses	58	30	35	18	8
Operating loss	−58	−30	−35	−18	−8
Interest expense	0	749,308	906,270	—	—
Interest income	2	3	99,974	19,011	−3
Gain from asset sale	−360,750	−1	307,086	0	—
Other expense	502	2,200	−3	—	—
Total other (income) expense, net	−2	−4	3	1	672,368
Loss before income taxes	−56	−27	−38	−19	−9
Provision for income taxes	5,400	10,071	3,600	6,741	2,100
Net loss	−56	−27	−38	−19	−9
Basic (in dollars per share)	−1.41	−0.73	−5.37	−8.77	−0.02
Diluted (in dollars per share)	−1.41	−0.73	−5.37	−8.77	−0.02
Basic (in shares)	40	36	7	2	407
Diluted (in shares)	40	36	7	2	407

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	6	68	1	—	—
Short-term investments	20	0	—	—	—
Prepaid expenses	504,890	201,962	194,259	780,807	554,217
Other current assets	852,036	2	1	481,588	56,870
Total current assets	27	71	12	9	10
Property and equipment, net	898,930	1	43,276	87,854	87,710
Operating lease right-of-use asset	266,646	449,864	237,983	71,191	146,972
Other assets	53,910	53,910	8,309	8,309	8,309
Total assets	28	73	12	9	10
Accounts payable	2	569,252	—	2	897,880
Accrued payroll liabilities	1	1	888,381	657,734	344,450
Other current liabilities	3	654,201	—	1	375,842
Estimate for accrued legal contingencies and related expenses	2	2	6	6	0
Operating lease liability, current portion	189,647	182,428	72,038	78,700	82,372
Total current liabilities	8	4	14	12	4
Operating lease liability, net of current portion	83,999	273,162	171,230	0	78,700
Total liabilities	8	5	14	12	4
Commitments and contingencies (Note 12)	—	—	—	—	—
Preferred stock, $0.001 par value; 200,000 shares authorized at December 31, 2025 and 2024; no shares issued and outstanding at December 31, 2025 and 2024	0	0	0	0	0
Common stock, $0.001 par value; 100,000,000 shares authorized at December 31, 2025 and 2024, respectively; 33,378,139 and 30,974,559 shares issued and outstanding at December 31, 2025 and 2024, respectively	33,379	30,975	12,349	3,654	476,108
Additional paid-in-capital	207	199	102	64	53
Accumulated deficit	−187	−131	−104	−67	−47
Total stockholders equity	20	68	−2	−3	6
Total liabilities and stockholders equity	28	73	12	9	10

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Write-down of vendor deposits	0	325,610	0	—	—
Depreciation and amortization	723,352	298,640	124,251	—	—
Net loss on disposal of asset	0	10,794	−4,080	0	—
Stock-based compensation expense	8	8	987,510	629,032	869,206
Amortization of debt discount	0	599,006	329,890	489,595	593,802
Prepaid expenses	−302,928	−7,703	795,232	−16,396	−364,083
Other current assets	1	−1	−488,790	112,907	−56,595
Other assets	0	−45,601	0	0	−8,309
Accounts payable	1	−586,533	−576,384	688,269	533,540
Accrued payroll liabilities	155,219	225,874	230,647	313,284	282,903
Other current liabilities	2	−344,351	−493,472	−2	166,531
Operating lease liability	−181,944	−94,442	−76,566	−82,372	−9,534
Net cash, cash equivalents used in operating activities	−43	−25	−14	−13	−6
Proceeds from asset sales, net of legal expenses	360,750	1	6	−66,458	0
Purchase of short-term investment	−20	0	—	—	—
Purchases of property and equipment	−6,312	−2	−12,550	−28,060	−90,866
Net cash, and cash equivalents used in investing activities	−20	−245,615	7	5	−90,866
Purchase under employee stock purchase plan	29,571	0	—	—	—
Proceeds from option exercises	0	5,618	0	0	4,783
Net cash, and cash equivalents provided by financing activities	29,571	84	16	−208,794	13
Net increase in cash and cash equivalents	−63	58	9	−8	7
Interest	0	433,336	198,352	333,547	44,087
Income taxes	5,400	5,200	3,600	6,741	1,600
Right of use asset obtained in exchange for operating lease liabilities	0	306,764	241,134	0	—
Conversion of convertible note - related party	0	5	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro